Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Anne Wojcicki

Behind the scenes at 23andMe, questions about a star CEO

Some past employees weren’t exactly surprised when the entire board at 23andMe tester quit last month

Fortune

A giant biotechnology company might be about to go bust. What will happen to the millions of people’s DNA it holds?

Since it was founded nearly two decades ago, 23andMe has grown into one of the largest biotechnology companies in the world. Millions of people have used its simple genetic testing service, which involves ordering a saliva test, spitting into a tube, and sending it back to the company for a…

The Conversation

23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable

The blue-chip board and the startup star had been on a collision course for months. Here’s what really happened.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Patient sues Kim Kardashian-endorsed MRI company for allegedly missing ‘obvious’ stroke signs

EXCLUSIVE: A crucial oversight led to disaster for father-of-two Sean Clifford, who can no longer dress himself, speak clearly, or move large portions of his body, according to a new lawsuit

The Independent UK

Exclusive: Avid Ventures raises $87 million second fund

Avid Ventures has raised $87 million for its second fund, Fortune can exclusively report.

Fortune

All 23andMe board members but CEO resign over no adequate buyout offers

The board has rejected both of Anne Wojcicki’s buyout proposals to save the struggling genetics company

The Guardian - US

Every single member of the board just resigned from DNA tester 23andMe

CEO Anne Wojcicki said the mass exodus left her “surprised and disappointed.”

Fortune

Read news from The Economist, FT, and more,
with one subscription

23andMe CEO Under Fire After Directors Resign From Board

Genetic-testing firm 23andMe was dealt a major blow in its effort to take the company public on Tuesday when its independent directors resigned from the board over what it called CEO Anne Wojcicki's lack of action on the matter.

International Business Times

Susan Wojcicki blazed a trail for women in Silicon Valley

The former YouTube CEO died at 56 after two years living with lung cancer.

Fortune

‘There are no serious safeguards’: can 23andMe be trusted with our DNA?

The at-home genetic testing company is dealing with financial woes and a data breach. What does that mean for customers?

The Guardian - US

23andMe's "minimum wage" billionaire

UPDATED: Data-hoarding billionaires don't go to jail — but if they violate our privacy, they can go broke

Salon

The human genome revealed its secrets 20 years ago. It’s time to fulfill its promise of personalized health care

Genetics have the potential to transform how we predict, prevent, and treat almost all human disease, writes 23andMe CEO Anne Wojcicki.

Fortune

YouTube CEO Susan Wojcicki's exit costs Silicon Valley one of its most influential female executives

She famously rented her garage to Google cofounders Larry Page and Sergey Brin in 1998.

Fortune

YouTube CEO steps down, severing longtime ties to Google

Susan Wojcicki, a longtime Google executive who played a key role in the company’s creation, is stepped down as YouTube’s CEO after spending the past nine years running the video site that has reshaped entertainment, culture and politics

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

How to be a CEO: 23andme’s Anne Wojcicki on revolutionising the biotech industry

Plus, the importance of instant feedback

The Independent UK

Google co-founder Sergey Brin divorcing from wife Nicole Shanahan, court documents show

Proceedings began in January, records show

StockNews.com

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.